Semaglutide eases osteoarthritis
A March 2026 Cell Metabolism study reports semaglutide may slow osteoarthritis progression — expanding potential benefits beyond weight loss and metabolic control. The finding raises the possibility that GLP‑1s could alter joint disease biology, not just reduce biomechanical load from weight loss. Semaglutide may slow osteoarthritis damage, study finds
The paper by Hongyu Qin et al. was published online Feb. 9, 2026 (DOI 10.1016/j.cmet.2026.01.008). painresearchforum.org The team combined obese mouse osteoarthritis models with a randomized pilot clinical study registered as ChiCTR2200066291 to test semaglutide’s effects under a diet‑controlled protocol. painresearchforum.org At the cellular level the authors report semaglutide signals through the “GLP‑1R‑AMPK‑PFKFB3” axis and reprograms chondrocyte metabolism from glycolysis toward oxidative phosphorylation. sciencedirect.com In mice the paper documents reductions in cartilage degeneration, osteophyte formation, synovial lesions and pain sensitivity; the small human pilot—reported in media coverage—enrolled about 20 adults aged 50–75 and tested semaglutide plus intra‑articular hyaluronic acid vs. control. painresearchforum.org Those mechanistic findings were framed against larger clinical data: the 68‑week STEP 9 trial (407 participants) previously showed once‑weekly semaglutide 2.4 mg reduced body weight and WOMAC knee pain scores, with reported mean weight loss around 13.7%. ryortho.com Qin and coauthors explicitly describe semaglutide as a candidate for “metabolic OA” therapy and call for larger, controlled clinical trials to confirm cartilage‑restorative effects observed in mice and the pilot study. painresearchforum.org
